Genzyme and AnorMED Announce Completion of Hart-Scott-Rodino Review
07 11월 2006 - 2:01PM
PR Newswire (US)
CAMBRIDGE, Mass. and VANCOUVER, B.C., Nov. 7 /PRNewswire-FirstCall/
-- Genzyme Corporation (NASDAQ:GENZ) and AnorMED Inc. (Nasdaq:
ANOR; TSX: AOM) announced today the expiration of the waiting
period under the Hart-Scott- Rodino Antitrust Improvements Act of
1976 with respect to Genzyme's tender offer to acquire the
outstanding shares of AnorMED. Genzyme and AnorMED announced on
October 17, 2006 that they had entered into a support agreement
pursuant to which Genzyme expects to acquire AnorMED in an all cash
transaction valued at $13.50 per outstanding share, or
approximately $580 million. Genzyme's offer is set to expire today
at 8:00 a.m. Vancouver time. About Genzyme One of the world's
leading biotechnology companies, Genzyme is dedicated to making a
major positive impact on the lives of people with serious diseases.
This year marks the 25th anniversary of Genzyme's founding. Since
1981, the company has grown from a small start-up to a diversified
enterprise with more than 8,500 employees in locations spanning the
globe and 2005 revenues of $2.7 billion. Genzyme has been selected
by FORTUNE as one of the "100 Best Companies to Work for" in the
United States. With many established products and services helping
patients in more than 80 countries, Genzyme is a leader in the
effort to develop and apply the most advanced technologies in the
life sciences. The company's products and services are focused on
rare inherited disorders, kidney disease, orthopedics, cancer,
transplant and immune diseases, and diagnostic testing. Genzyme's
commitment to innovation continues today with a substantial
development program focused on these fields, as well as heart
disease and other areas of unmet medical need. Important
Information Regarding the Tender Offer Investors and security
holders are urged to read the disclosure documents filed with the
Securities and Exchange Commission (the "SEC") from time to time,
including the tender offer statement filed on September 1, 2006, as
amended, regarding the tender offer by Genzyme's wholly owned
subsidiary, Dematal Corp., for all of the outstanding common shares
of AnorMED. Investors and security holders may obtain a free copy
of the disclosure documents and other documents filed by Genzyme or
Dematal with the SEC at the SEC's website at http://www.sec.gov/.
In addition, documents filed with the SEC by Genzyme or Dematal may
be obtained free of charge from Genzyme by directing a request to
Sally Curley at (617)768-6140. Genzyme(R) is a registered trademark
of Genzyme Corporation. All rights reserved. Genzyme's press
releases and other company information are available at
http://www.genzyme.com/ and by calling Genzyme's investor
information line at 1-800-905-4369 within the United States or
1-703-797-1866 outside the United States. CONTACTS: For AnorMED For
Genzyme Kenneth Galbraith (investors) Sally Curley (investors)
(604) 889-5320 (617) 768-6140 Karen Cook Boas (media) Dan Quinn
(media) (604) 742-4252 (617) 768-6849 DATASOURCE: Genzyme
Corporation CONTACT: Kenneth Galbraith (investors),
+1-604-889-5320, or Karen Cook Boas (media), +1-604-742-4252, both
For AnorMED; or Sally Curley (investors), +1-617-768-6140, or Dan
Quinn (media), +1-617-768-6849, both for Genzyme Web site:
http://www.genzyme.com/ Company News On-Call:
http://www.prnewswire.com/comp/104284.html
Copyright